Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2022 U.S. Biopharma Recap

An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Navigating China’s Restrictions and the U.S. Response

    The Department of Defense has invested more than $439 million in rare earth projects since 2020. Learn more about how these elements are essential to modern technology.

    Read more

  • Economics Weekly: Modern Day Engels’ Pause Is Not the Inevitable Outcome of AI

    In this Economics Weekly, Richard de Chazal constructs a few scenarios around the current AI revolution and why we should not view that outcome as an unfortunate accident, but rather as a result of the decisions we make today.

    Read more

  • William Blair Initiates Coverage of Two Companies in the Medical Technology Industry

    William Blair initiated research coverage of Stryker Corporation (SYK $377.32) and Zimmer Biomet Holdings, Inc. (ZBH $98.25), two leading global medical technology companies.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures